Table 1 Absolute IC50 values of CB-839, metformin, phenformin and chloroquine upon 72 h of treatment, as determined by PrestoBlue Cell Viability
From: Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
Compound/cell line | CB-839 (μM) | Metformin (mM) | Phenformin (μM) | Chloroquine (μM) | IDH1/2 status | Reference |
|---|---|---|---|---|---|---|
HT1080 | 0.1 | 1.20 | 17.1 | 19.5 | IDH1 p.Arg132Cys | Rasheed et al.30 |
JJ012 | 4.6 | 19.0 | 504.1 | 27.1 | IDH1 p.Arg132Gly | Scully et al.28 |
L835 | >50 | >20 | 870.3 | 31.1 | IDH1 p.Arg132Cys | Van Oosterwijk et al.29 |
SW1353 | 0.2 | 8.26 | 74.5 | 24.6 | IDH2 p.Arg172Ser | ATCC |
L2975 | 10.2 | 10.6 | 116.6 | 30.5 | IDH2 p.Arg172Trp | Van Oosterwijk et al.29 |
CH2879 | >50 | 10.9 | 193.7 | 57.9 | WT | Gil Benso et al.31 |
NDCS1 | 13.5 | 18.1 | 187.9 | 16.7 | WT | Kudo et al.34 |
CH3573 | 17.5 | >20 | 343.4 | 34.0 | WT | Calabuig-Farinas et al.33 |
L3252b | >50 | 16.7 | >1000 | 39.4 | WT | Van Oosterwijk et al.29 |
MCS170 | >50 | 10.5 | 294.7 | 14.4 | WT | De Jong et al.32 |
